Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

NICE decides against recommending drug for enlarged spleen


NICE has confirmed it is not recommending the use of a drug to treat disease-related splenomegaly - enlarged spleen - on the NHS.

It has published final draft guidance detailing its decision on the Novartis drug Jakavi (ruxolitinib) for the treatment of disease-related splenomegaly or its symptoms in adults with primary myelofibrosis, a rare blood cancer.

The decision also related to those with post polycythaemia vera myelofibrosis and post essential thrombocythaemia myelofibrosisi.

In patients with myelofibrosis, the bone marrow produces too many cells too quickly, causing the marrow to become scarred and less able to produce blood cells, which prompts other organs such as the liver and spleen to compensate by producing them.

The spleen then becomes enlarged as it starts to produce blood cells.

Ruxolitinib was found by the independent committee to be clinically effective in reducing spleen size and symptoms such as itch and fatigue.

It concluded, however, that it was not a more cost-effective option than the best therapy currently available.

The committee found plausibility in the suggestion that the drug could offer survival benefits but noted uncertainties in the evidence, which failed to establish why this may be the case.

It also noted fundamental issues surrounding the manufacturer’s economic model for the drug, which in turn impacted on its cost-effectiveness.

NICE chief executive Sir Andrew Dillon expressed disappointment at not being able to recommend the drug and acknowledged the symptoms of itching and fatigue associated with myelofibrosis and splenomegaly “can be extremely debilitating”.

However, he stressed that to recommend it “we have to be sure that the treatment is both clinically and cost-effective, because money has to be diverted from elsewhere in the health service to pay for it”.


Readers' comments (2)

  • I have been Jakafi for 16 months, and my spleen has shrunk 50%!

    Unsuitable or offensive? Report this comment

  • National Institute for Clinical EXCELLENCE?


    perhaps a different, more sensible and less suggestive name would be more appropriate?

    " has to be diverted from elsewhere in the health service to pay for it”."

    there are areas where the money is being wasted which could be used to alleviate suffering and provide the best possible treatment outcome to suit the needs of each individual. It is a question of priorities and competency in clinical decision-making!

    The drug industry also needs better regulation to ensure that medication is effective, safe and affordable.

    Unsuitable or offensive? Report this comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs